Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YMH
|
|||
| Former ID |
DAP000970
|
|||
| Drug Name |
Lumiracoxib
|
|||
| Synonyms |
Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Knee osteoarthritis [ICD-11: FA01; ICD-9: 715] | Approved | [1], [2] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13ClFNO2
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
|
|||
| InChI |
1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
|
|||
| InChIKey |
KHPKQFYUPIUARC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 220991-20-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6889610, 10251040, 12015303, 14898109, 17397805, 46227733, 46506378, 50069519, 50070561, 50071183, 50126342, 50146068, 57347306, 76715547, 81041141, 81145916, 92718829, 103562109, 104084914, 104430341, 121362203, 123043886, 125345177, 126628436, 126645712, 126669886, 128383506, 131305772, 134338241, 135106949, 136948146, 137001909, 139667196, 144162368, 144207115, 152034557, 160661707, 160661708, 160964604, 162009833, 162169214, 163108814, 164786748, 166237623, 170465597, 172659601, 175610946, 178100246, 179150172, 184545760
|
|||
| ChEBI ID |
CHEBI:73044
|
|||
| SuperDrug ATC ID |
M01AH06
|
|||
| SuperDrug CAS ID |
cas=220991208
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2897). | |||
| REF 2 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | |||
| REF 3 | Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.